Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Drops By 26.3%

Posted by Faye Duncan on Nov 29th, 2024

Vincerx Pharma, Inc. (NASDAQ:VINC – Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 600,000 shares, a drop of 26.3% from the October 31st total of 813,800 shares. Based on an average trading volume of 524,300 shares, the short-interest ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners cut their price objective on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Read Our Latest Analysis on VINC

Vincerx Pharma Stock Up 7.9 %

Shares of VINC stock traded up $0.02 during trading hours on Friday, reaching $0.28. The stock had a trading volume of 126,328 shares, compared to its average volume of 668,220. The firm has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.60. Vincerx Pharma has a twelve month low of $0.24 and a twelve month high of $9.37.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC acquired a new stake in shares of Vincerx Pharma during the second quarter worth $1,610,000. Vanguard Group Inc. lifted its stake in Vincerx Pharma by 29.9% during the first quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after buying an additional 153,575 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Vincerx Pharma by 359.1% in the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after acquiring an additional 256,967 shares in the last quarter. 44.02% of the stock is owned by institutional investors and hedge funds.

Vincerx Pharma Company Profile

(Get Free Report)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.